Payment overview · 2025
General Payments
$1,735.17
86 reported records · 22 companies
Healthcare provider profile · identity verified
Mohan C Deochand, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · SANFORD, NC · NPI 1518976729
Verified facts
What the public records show
CMS Open Payments records show Mohan C Deochand, MD received $1,735.17 in general payments during 2025 across 86 reported records.
PFIZER INC. accounted for 12.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 33 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gammaked, Nurtec Odt, Ubrelvy, Vumerity.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ubrelvy by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TECFIDERA as an associated drug or biological on 28 records involving 22 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tecfidera by this doctor in 2024.
Biogen, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUMERITY as an associated drug or biological on 16193 records involving 4044 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vumerity by this doctor in 2024.
JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EPIDIOLEX as an associated drug or biological on 10990 records involving 3626 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Epidiolex by this doctor in 2024.
Kedrion Biopharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAKED as an associated drug or biological on 761 records involving 541 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Gammaked by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nurtec Odt by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GAMMAGARD LIQUID as an associated drug or biological on 29 records involving 8 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Gammagard Liquid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $214.36 | 12.3% | 14 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$185.42 | 10.7% | 8 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $166.67 | 9.6% | 7 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $148.20 | 8.5% | 7 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $136.42 | 7.9% | 7 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $89.08 | 5.1% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $87.85 | 5.1% | 3 | 2025 |
| Avadel CNS Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $73.90 | 4.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $73.16 | 4.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $64.12 | 3.7% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $61.49 | 3.5% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $59.41 | 3.4% | 3 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $57.21 | 3.3% | 3 | 2025 |
| Kedrion Biopharma, Inc. | Unresolved — no canonical attribution shown | $54.37 | 3.1% | 3 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $50.32 | 2.9% | 3 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $49.94 | 2.9% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $38.82 | 2.2% | 2 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $35.31 | 2.0% | 2 | 2025 |
| LivaNova USA, Inc. | Unresolved — no canonical attribution shown | $34.80 | 2.0% | 2 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $23.26 | 1.3% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $16.13 | 0.9% | 1 | 2025 |
| PROTEGA PHARMACEUTIALS INC | Unresolved — no canonical attribution shown | $14.93 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,735.17 | 86 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $214.36 | 14 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $185.42 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $179.68 | 13 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $166.67 | 7 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $148.20 | 7 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $87.85 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $76.24 | 4 | 2025 |
Source payment records
|
|||||
| LUMRYZ Normalized: lumryz |
Drug | Avadel CNS Pharmaceuticals, LLC | $73.90 | 4 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $73.56 | 4 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc., Eisai Inc. | $72.73 | 4 | 2025 |
Source payment records
|
|||||
| ETERNA Normalized: eterna |
Device | Abbott Laboratories | $61.49 | 1 | 2025 |
Source payment records
|
|||||
| NUEDEXTA Normalized: nuedexta |
Drug | Otsuka America Pharmaceutical, Inc. | $60.18 | 3 | 2025 |
Source payment records
|
|||||
| Albuked Normalized: albuked |
Biological | Kedrion Biopharma, Inc. | $54.37 | 3 | 2025 |
Source payment records
|
|||||
| GAMMAKED Normalized: gammaked |
Biological | Kedrion Biopharma, Inc. | $54.37 | 3 | 2025 |
Source payment records
|
|||||
| KEDRAB Normalized: kedrab |
Biological | Kedrion Biopharma, Inc. | $54.37 | 3 | 2025 |
Source payment records
|
|||||
| KOATE Normalized: koate |
Biological | Kedrion Biopharma, Inc. | $54.37 | 3 | 2025 |
Source payment records
|
|||||
| RhoGAM Ultra-Filtered PLUS Normalized: rhogam ultra filtered plus |
Biological | Kedrion Biopharma, Inc. | $54.37 | 3 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $50.32 | 3 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $49.94 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $40.29 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $40.29 | 2 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.93 | 2 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $35.31 | 2 | 2025 |
Source payment records
|
|||||
| VNS THERAPY SENTIVA MODEL 1000 GENERATOR Normalized: vns therapy sentiva model 1000 generator |
Device | LivaNova USA, Inc. | $34.80 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.64 | 2 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $29.48 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $23.26 | 1 | 2025 |
Source payment records
|
|||||
| AJOVY Normalized: ajovy |
Biological | Teva Pharmaceuticals USA, Inc. | $21.48 | 1 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $20.39 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $16.13 | 1 | 2025 |
Source payment records
|
|||||
| ROXYBOND Normalized: roxybond |
Drug | PROTEGA PHARMACEUTIALS INC | $14.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GAMMAKED gammaked |
2025 | Gammaked | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VUMERITY vumerity |
2025 | Vumerity | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | TECFIDERA open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 22 recipient NPIs · example record 1208304358 |
Tecfidera · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Biogen, Inc. Exact reporting entity; no affiliate inference |
2025 | VUMERITY open payments reported associated product |
CMS Open Payments — General Payments 16193 supporting records · 4044 recipient NPIs · example record 1208299697 |
Vumerity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference |
2025 | EPIDIOLEX open payments reported associated product |
CMS Open Payments — General Payments 10990 supporting records · 3626 recipient NPIs · example record 1234297758 |
Epidiolex · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Kedrion Biopharma, Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAKED open payments reported associated product |
CMS Open Payments — General Payments 761 supporting records · 541 recipient NPIs · example record 1206766586 |
Gammaked · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | GAMMAGARD LIQUID open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 8 recipient NPIs · example record 1223786557 |
Gammagard Liquid · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 426 | 87 |
| Memantine Hcl | Memantine Hcl | 356 | 61 |
| Levetiracetam | Levetiracetam | 338 | 58 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 318 | 43 |
| Tizanidine Hcl | Tizanidine Hcl | 264 | 74 |
| Topiramate | Topiramate | 228 | 49 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 139 | 43 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 134 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 128 | 24 |
| Pregabalin | Pregabalin | 118 | 26 |
| Donepezil Hcl | Donepezil Hcl | 114 | 39 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 109 | 19 |
| Oxycodone Hcl | Oxycodone Hcl | 109 | 13 |
| Atorvastatin Calcium | Atorvastatin Calcium | 106 | 36 |
| Lacosamide | Lacosamide | 103 | 12 |
| Baclofen | Baclofen | 95 | 21 |
| Promethazine Hcl | Promethazine Hcl | 93 | 22 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 83 | 15 |
| Carbamazepine | Carbamazepine | 78 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 26 |
| Ropinirole Hcl | Ropinirole Hcl | 78 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 77 | 18 |
| Lamotrigine | Lamotrigine | 61 | suppressed |
| Ibuprofen | Ibuprofen | 59 | 13 |
| Amlodipine Besylate | Amlodipine Besylate | 51 | 20 |
| Eszopiclone | Eszopiclone | 49 | 16 |
| Primidone | Primidone | 48 | 11 |
| Sertraline Hcl | Sertraline Hcl | 48 | suppressed |
| Lisinopril | Lisinopril | 46 | 11 |
| Methocarbamol | Methocarbamol | 45 | 13 |
| Aimovig Autoinjector | Erenumab-Aooe | 43 | suppressed |
| Phenobarbital | Phenobarbital | 43 | suppressed |
| Ondansetron Odt | Ondansetron | 42 | suppressed |
| Omeprazole | Omeprazole | 37 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 36 | suppressed |
| Losartan Potassium | Losartan Potassium | 35 | suppressed |
| Diazepam | Diazepam | 34 | suppressed |
| Methylprednisolone | Methylprednisolone | 34 | suppressed |
| Alprazolam | Alprazolam | 33 | suppressed |
| Carbamazepine Er | Carbamazepine | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 33 | suppressed |
| Clonazepam | Clonazepam | 33 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 33 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Meloxicam | Meloxicam | 32 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 31 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 31 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 30 | suppressed |
| Famotidine | Famotidine | 30 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 30 | 14 |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Fycompa | Perampanel | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 11 |
| Nurtec Odt | Rimegepant Sulfate | 28 | suppressed |
| Amoxicillin | Amoxicillin | 26 | 16 |
| Dilantin | Phenytoin Sodium Extended | 26 | suppressed |
| Furosemide | Furosemide | 25 | suppressed |
| Prednisone | Prednisone | 24 | suppressed |
| Phenytoin | Phenytoin | 22 | suppressed |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 21 | suppressed |
| Simvastatin | Simvastatin | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 19 | suppressed |
| Ubrelvy | Ubrogepant | 18 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Vimpat | Lacosamide | 17 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Gammagard Liquid | Immun Glob G(Igg)/Gly/Iga Ov50 | 15 | suppressed |
| Lamotrigine Odt | Lamotrigine | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Dimethyl Fumarate | Dimethyl Fumarate | 14 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 14 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | suppressed |
| Epidiolex | Cannabidiol (Cbd) | 13 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 13 | suppressed |
| Lorazepam | Lorazepam | 13 | suppressed |
| Methsuximide | Methsuximide | 13 | suppressed |
| Modafinil | Modafinil | 13 | suppressed |
| Dalfampridine Er | Dalfampridine | 12 | suppressed |
| Tecfidera | Dimethyl Fumarate | 12 | suppressed |
| Vumerity | Diroximel Fumarate | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 11 | suppressed |
| Mirtazapine | Mirtazapine | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,735.17 · 86 records | PFIZER INC. | ACTHAR, AJOVY, AUSTEDO XR, Albuked, BRIUMVI, ETERNA, GAMMAKED, HYQVIA, INSPIRE, KEDRAB, KISUNLA, KOATE, LEQEMBI, LUMRYZ, Motpoly XR, NUEDEXTA, NURTEC ODT, QULIPTA, REXULTI, ROXYBOND, RhoGAM Ultra-Filtered PLUS, Sunosi, Symbravo, UBRELVY, VALTOCO, VNS THERAPY SENTIVA MODEL 1000 GENERATOR, VUMERITY, VYALEV, VYEPTI, WAKIX, XYWAV, ZAVZPRET, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gammaked play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error